The University of Georgia is partnering in a biopharmaceutical innovation institute that aims to boost market production of cell-based therapies and develop a skilled workforce to work in the biotechnology and pharmaceutical industry.The new public-private partnership, called the National Institute for Innovation of Manufacturing Biopharmaceuticals (NIIMBL) will focus its efforts on driving down the cost and risks associated with manufacturing advanced cell and gene therapies for biopharmaceutical production.Steven Stice, director of the UGA’s Regenerative Bioscience Center and D.W. Brooks Distinguished Professor in the UGA College of Agricultural and Environmental Sciences, is the UGA lead in the partnership, which is coordinated by the University of Delaware.NIIMBL represents a total investment of $250 million, including $129 million in private cost-share commitments from the NIIMBL consortium of 150 companies, nonprofits, educational institutions and state partners across the country, combined with at least $70 million in federal funding from the U.S. Department of Commerce.NIIMBL is the 11th institute under the Manufacturing USA National Network for Manufacturing Innovation initiative created to advance manufacturing leadership and restore jobs to the U.S.This recent success follows an announcement in 2016 by the U.S. Department of Defense that an MIT-led team involving UGA was selected for funding as the eighth NNMI institute.“We are pleased to have UGA participate in these high-profile public-private partnerships that are aimed at advancing U.S. leadership in key manufacturing sectors,” said UGA Vice President for Research David Lee. “We are eager to assist industry partners in meeting their goals through the development of new and existing intellectual property, and the training of an appropriate workforce.”Biopharmaceuticals are increasingly showing promising results in treating some of the most prevalent and debilitating diseases affecting human health. But manufacturing of biopharmaceuticals is not without large-scale operational and technological challenges, Stice said.These biologically sourced drugs are different from traditional small molecule, synthesized drugs. For example, he said, the synthesized drug ibuprofen can be precisely copied and characterized, and result in varied generic versions. In contrast, biopharmaceuticals like vaccines are much more complex and rely on the use of a biological transformation. As living cells, they are highly sensitive to their conditions and surroundings.Technical projects, which will be designed by the industry partners of the institution, will be selected through a competitive process and funded via subaward agreements with NIIMBL members.Stice, a Georgia Research Alliance Eminent Scholar, will facilitate team assembly for response to the project calls, leveraging years of collective experience in regenerative medicine and technology development. He is also co-director of the Regenerative Engineering and Medicine research center, or REM, a collaboration by Emory University, the Georgia Institute of Technology and UGA. “There is a crippling regulatory gap, which is commonly referred to as ‘the valley of death’ in moving biotech products from discovery to commercialization,” Stice said. “What NIIMBL presents is an opportunity to help improve government regulation, minimize failure, create job growth and improve health care quality, all while reducing costs in the U.S.”For more information about the role UGA’s Regenerative Bioscience Center plays in developing biotechnology that will shape the future visit www.rbc.uga.edu.
By Simon EvansMANCHESTER, England (Reuters) – Manchester United ended Liverpool’s 100 percent start to the Premier League season — and their 17 match winning streak — with a 1-1 draw at Old Trafford on Sunday.But there was disappointment for Ole Gunnar Solskjaer’s side who were five minutes away from a surprise win before Liverpool substitute Adam Lallana grabbed an equaliser for the league leaders to cancel out Marcus Rashford’s 36th minute opener.It was yet another Premier League game with VAR controversy which will continue to provoke debate about the system introduced this season.The result cuts Liverpool’s lead over second-placed Manchester City to six points and Juergen Klopp’s side were far from their best.“We were good enough for a point,” said Klopp, “We were in charge 100% towards the end. We wanted a different result but to do that you have to play better.”United are now unbeaten in their last seven home games against Liverpool and while their battling display will boost morale, the 20-times champions are adrift in 13th place, 15 points behind the leaders.“We have a team that works for each other and maybe this will turn their season,” said Solskjaer.“They are disappointed because they feel we should have won. Our fans showed they can see what’s happening and we will get there.”It has been many years since United went into this fixture as clear underdogs with just two victories from their opening eight games.On paper, the United line-up matched up poorly against Klopp’s side, especially with Paul Pogba out injured and Anthony Martial restricted to the bench as he returned from an injury lay-off.Liverpool were without Egyptian striker Mohamed Salah, who was ruled out with an ankle injury with Divock Origi given a rare start alongside Roberto Firmino and Sadio Mane in attack while Brazilian keeper Alisson Becker returned from injury.Solskjaer’s headaches were added to when defender Axel Tuanzebe was injured during the warm-up, meaning Argentine Marcos Rojo had to be thrust into the starting 11.But from the outset, United worked tirelessly, chasing down the ball in midfield and grew in belief while Liverpool never found their usual standard of fluency and invention.Rashford scored after turning home a superb low cross from Dan James after the speedy Welshman had broken down the right flank.The goal was subject to a video review and allowed to stand despite Liverpool claims that Victor Lindelof had fouled Origi at the start of the move.Liverpool thought they had got level, two minutes before the interval, when Mane outfought Lindelof and poked home but the VAR review showed the Senegalese forward had handled the ball.But Klopp’s side, who had struggled to find openings, finally broke through in the 85th minute when Lallana slotted home Andy Robertson’s low cross.
Moradi denied the allegations in court. He and Brees had a 15-year business relationship. Attorney Andrew Kim, who co-represented the Breeses, expressed support for the jury’s decision. Related News A jury has awarded New Orleans Saints quarterback Drew Brees and his wife $6.13 million in a lawsuit claiming a San Diego-area jeweler sold them overpriced diamonds.Brees and his wife, Brittany, had sued Vihad Moradi of CJ Charles Jewelers in La Jolla, California, claiming he misled them about the value of $15 million in diamonds they purchased as an investment. Saints offering $18M per year, Michael Thomas wants $22M, report says Colts owner Jim Irsay spends record $3.975M on Pink Floyd guitar “It was our position that Mr. Moradi breached his fiduciary duty, and that’s essentially what the jury said,” Kim said (via the San Diego Union-Tribune). “They saw Mr. Moradi for exactly what he is: a grifter and a confidence man.”Brees played for the San Diego Chargers from 2001 through 2004 before signing as a free agent with the Saints.